EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

NeuMoDx™ Molecular was recently at ECCMID displaying our NeuMoDx™ Molecular 288 System. Our system is capable of automated extraction and isolation of nucleic acids from multiple specimen types, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Listen to Jeff Williams, Chairman and CEO of NeuMoDx™ Molecular, explain why the NeuMoDx™ system is...

NeuMoDx™ platforms are built to handle large volumes of sample in an automated fashion, integrating the entire molecular diagnostic process from sample to result. Dr. Steven Young, Director of Research and Clinical Trials at TriCore Reference Laboratories, has been working with NeuMoDx™ on an invitro diagnostics test approved by the FDA, using our instrumentation. Let Dr....

The NeuMoDx™ 96 and 288 Molecular Systems were formally launched at the QIAGEN booth at ESCV 2018 in Athens, Greece, provided robust feedback from clinicians, researchers, lab workers and industry members. Listen to what people are saying about our systems by watching the video below.

The NeuMoDx™ 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. The NeuMoDx™ 288 Molecular System consists of the instrument with touchscreen computer, accessories and reagents and consumables. Learn more about the NeuMoDx™ 288...












































































Coronavirus Assay Information

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.

To learn more about SARS-CoV-2 testing, click here.
To order, click here.